growth of acetazolamide market. Acetazolamide capsule taken once a day by patients with
chronic glaucoma offers a substantial pressure-lowering effect, which lasts at least 23 hours.
Report includes chapters which deeply display the following deliverable about industry :
• Acetazolamide Market Research Objective and Assumption
• Acetazolamide Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Acetazolamide Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Acetazolamide Market, By Regions
• Acetazolamide Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Acetazolamide Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Acetazolamide Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Acetazolamide Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Extended Application of Acetazolamide in Various Treatment Modalities is expected to Drive
Market Growth during the Forecast Period
Acetazolamide is used to prevent high altitude illness in most people, which is characterized by
headache, nausea, vomiting, and tiredness (often called acute mountain sickness), but may
affect the brain or the lungs in different individuals. As per the study published in Cochrane
Journal, in June 2017, acetazolamide is an effective and better treatment for the prevention of
acute high altitude illness (HAI) in dosages of 250 to 750 mg/day, when compared to a
placebo. Acetazolamide prevents acute mountain sickness and has fewer side effects than
alternative drugs such as dexamethasone. According to BMJ journal, May 2018, prescribing